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Abstract
We introduce the modification of bacteriophage particles with aptamers for the use as 
bioanalytical reporters, and demonstrate the use of these particles in ultrasensitive lateral flow 
assays. M13 phage displaying an in vivo biotinylatable peptide (AviTag) genetically fused to the 
phage tail protein pIII were used as reporter particle scaffolds, with biotinylated aptamers attached 
via avidin-biotin linkages, and horseradish peroxidase (HRP) reporter enzymes covalently 
attached to the pVIII coat protein. These modified viral nanoparticles were used in 
immunochromatographic sandwich assays for the direct detection of IgE and of the penicillin-
binding protein from Staphylococcus aureus (PBP2a). We also developed an additional lateral 
flow assay for IgE, in which the analyte is sandwiched between immobilized anti-IgE antibodies 
and aptamer-bearing reporter phage modified with HRP. The limit of detection of this LFA was 
0.13 ng/mL IgE, ~100 times lower than those of previously reported IgE assays.
INTRODUCTION
Lateral flow assays (LFAs), in which reporter particles are transported by capillary wicking 
in a porous material and accumulate to form a visible line in the presence of analyte, are 
widely used because of their convenience, low cost, and adaptability to use at the point-of-
care 1-3. LFAs most often employ antibodies as recognition elements, but nucleic acid 
recognition elements have increasingly been employed, not just in lateral flow nucleic acid 
hybridization assays 4, but also in protein detection assays where target-specific RNA or 
DNA aptamers serve as the molecular recognition element 1,5-9. Signal readout is most 
commonly achieved by using visible nanoparticles (gold, blue latex, or carbon). But even if 
the classic LFA is a brilliant approach to delivering assays in a rapid and easy-to-use format, 
the LFA limits of detection (LOD) lag behind more complex laboratory methods, e.g. 
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ELISA. Thus the development of alternative LFA readout reporters to increase assay 
sensitivity is a topic of great commercial and academic interest.
Bacteriophages have been explored in recent years for use as reporters for immunoassays 
that enable both improved recognition and enhanced signal readout. The surface of phage, 
consisting of multiple copies of identical coat proteins, can be readily modified using well-
established chemistries 10-13. M13 phage, in particular, have been modified with recognition 
elements (e.g. antibodies) and/or reporter elements (e.g. Horseradish peroxidase (HRP), 
fluorophores), and have been successfully used in various protein or small molecule 
detection assays, e.g. enzyme-linked immunosorbent assays (ELISA) 14-16, microarrays 17 
or other protein sensors 18,19. PCR amplification of the phage genetic material has led to the 
development of ultra-sensitive immuno-phage PCR assays by ourselves and others 20-22.
We recently introduced the use of engineered bacteriophage particles as reporters in lateral 
flow assays 23-25. M13 phage particles functionalized with both target-specific antibodies 
and enzyme reporters were integrated into an immunochromatographic lateral flow assay 
(LFA) for the detection of a model virus (MS2), leading to greatly enhanced detection 
sensitivity (one thousand-fold better than a conventional gold nanoparticle LFA using the 
same antibodies). Our strategy often relies upon a phage-displayed “AviTag” peptide 26-28 
which can be biotinylated by biotin ligase, either in vivo during phage assembly in 
Escherichia coli or in vitro through treatment of purified phage particles with the enzyme 24. 
This strategy also allows the convenient modification of phage reporter particles with any 
biotinylated molecular recognition agent, including antibodies and (as introduced here) 
aptamers.
Here we report the use of engineered phage particles modified with aptamers on their tail 
proteins and bearing reporter enzymes, in lateral flow assays with improved limits of 
detection, compared to a conventional gold nanoparticle assay. The conjugation of aptamers 
to phage constitutes a novel and promising approach to the point-of-care detection of 
proteins. This approach may also readily be extended to the development of higher-
sensitivity lateral flow nucleic acid hybridization assays.
EXPERIMENTAL SECTION
Materials and Reagents
Polyclonal anti-IgE antibody was purchased from Fitzgerald Industries International (Acton, 
MA, USA). Human immunoglobulin E (IgE) was obtained from Abcam (Cambridge, MA, 
USA). An oligonucleotide bearing a 5’ biotin and TEG (triethylene glycol) spacer with 
sequence matching that of a previously-reported DNA aptamer binding human IgE 29 was 
purchased from Integrated DNA Technologies (Coralville, IA, USA) (Figure 1). In addition, 
an aptamer specific for the Staphylococcus aureus penicillin-binding protein 2a (PBP2a) (5’-
biotinylated; proprietary sequence), was purchased from Base Pair Technologies (Pearland, 
TX, USA). It is a DNA aptamer that was selected from a randomized 32-mer library against 
MRSA (Methicillin-resistant Staphylococcus aureus) protein. Since IgE aptamer is a DNA 
aptamer, a DNA aptamer (PBP2a) was used as an appropriate control for the aptamer-phage 
LFA. PBP2a protein was purchased from Ray Biotech (Norcross, GA, USA).
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Propagation and modification of SAM-AviTag Phage
SAM (for serine-amber)-AviTag M13 phage, a gift from Dr. Brian Kay, UIC (Chicago, IL, 
USA) 26,27,30, are derivatives of M13 phage displaying an AviTag peptide (a 15-amino-acid 
peptide that is a substrate for biotin ligase (BirA)) on the phage coat protein, pIII. The phage 
were propagated, titered, biotinylated and conjugated with horseradish peroxidase largely as 
previously described 24. Briefly, phage were initially grown on E. coli TG1 in LB medium at 
37 °C, and this infected culture was then transferred to 500 mL 2xTY 31 medium in a 2 L 
flask and incubated overnight at 37 °C on a shaker. After centrifugation, the phage-
containing supernatant was passed through a 0.45 μm filter and phage were purified by 
precipitation with 20% polyethylene glycol (PEG) in 2.5 M NaCl. Phage titers were 
determined by plaque assay on X-Gal/IPTG plates 32. The pIII protein of SAM-AviTag 
phage was enzymatically biotinylated using E. coli biotin ligase (Avidity, Aurora, CO) 
according to the manufacturer’s instructions; biotin ligase also can be prepared in-house as 
previously described 20. The efficiency of biotinylation was determined through an ELISA 
on streptavidin-coated microtiter plates (StreptaWell High Bind, Roche Applied Science, 
Indianapolis, IN). Subsequently, phage were activated using Traut’s reagent (2- 
iminothiolane-HCl, Thermo Fisher Scientific, Waltham, MA). 100 μL of a 1×1011 phage per 
mL solution were suspended in 800 μL phosphate-buffered saline (PBS), pH 7.4, 3 mM 
EDTA with a 20-fold molar excess of Traut's reagent. This reaction was continued for 90 
min at 25 °C on a rotator. Excess Traut's reagent was removed using a 10 kDa filter 
(Millipore, Billerica, MA). HRP (Sigma-Aldrich, St. Louis, MO) was modified with 
maleimide groups using sulfo-SMCC (succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-
carboxylate, Sigma-Aldrich) by mixing HRP and sulfo-SMCC at a final concentration of 22 
μM and 1.14 mM, respectively and incubating for 30 min. Excess sulfo-SMCC was removed 
using a 10 kDa filter. Traut’s reagent-activated phage and maleimide-HRP were then 
incubated together for 90 min at 25 °C (270,000 molecules of HRP were offered per phage). 
Uncoupled HRP was then removed using 100 kDa filters (Millipore). Subsequently, 1 μL of 
1 mg/mL of Neutravidin (Thermo Fisher Scientific) was then offered to the HRP-labeled 
phage and bound through the biotinylated AviTag displayed on phage protein pIII (100 
molecules of Neutravidin were offered per phage). Uncoupled Neutravidin was removed 
using 100 kDa filters (Millipore).
Aptamer modification of avidin phage
Biotinylated IgE aptamer (100 μl, 100 nM in PBS, pH 7.0, 1 mM MgCI2) was first heat-
denatured at 95 °C for 10 min (to disrupt any pre-existing higher-order structures that might 
interfere with phage functionalization and to allow the 5’biotin to interact freely with its 
avidin binding partner 33) and then slowly renatured at room temperature. Subsequently, the 
biotinylated IgE aptamer was added to 1012 neutravidin-functionalized phage in 100 μL 
PBS. The complex was incubated for 2 hrs at 25 °C before unconjugated IgE aptamer was 
removed using PEG precipitation (Figure 2). As a control, phage were functionalized with 
the anti-PBP2a aptamer in the same fashion. A series of 10-fold dilutions (105 to 1010 
phage/mL) of unmodified phage (titer obtained by plaque counting) was used as PCR 
calibration standards and the concentration of the various phage constructs was determined 
against that standard curve. The AviTag-targeted PCR primers were: Forward: 5’-
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GTTGTTTCTTTCTATTCTCACTCC-3’ and Reverse: 5’- 
CAGACGTTAGTAAATGAATTTTCTG -3’. For the phage amplification 0.1 μL of a 10 
μM stock of each primer were combined with 10 μL 2xPCR mix (Brilliant III Ultra-Fast 
SYBR mix, Agilent, Santa Clara, CA), 4.8 μL ultra-pure (RNase and DNase free) water and 
5 μL of each phage sample to achieve a total volume of 20 μL. The PCR conditions were: 10 
min at 95 °C, 40 cycles of 30 sec at 95 °C, 30 sec at 62 °C and 30 sec at 72 °C, followed by 
a dissociation step to detect possible contaminations (1 min at 95 °C, 30 sec at 55 °C, and 30 
sec at 95 °C).
Preparation of LFA strips
Figure 3 depicts the schematic of the aptamer-phage LFA. Polyclonal anti-human IgE rabbit 
serum (Fitzgerald Industries International, Acton, MA; 5 μl, diluted 100-fold in 50 mM 
sodium acetate buffer (pH 3.6) based on preliminary screening experiments) and 5 μL of 
rabbit polyclonal anti-M13 IgG antibodies (Novus Biologicals, Littleton, CO; 0.1 μg/μL in 
50 mM sodium acetate buffer (pH 3.6)) were used to make test and control lines respectively 
on Fusion 5 membranes (GE Healthcare, Piscataway, NJ) using a Lateral Flow Reagent 
Dispenser (Claremont BioSolutions, Upland, CA) equipped with an external syringe pump 
(Chemyx, Stafford, TX). The Fusion 5 membrane was cut into 7 mm × 50 mm strips using a 
guillotine paper cutter. CF5 membrane (GE Healthcare) was used as the absorbent pad (7 
mm × 25 mm) and Fusion 5 membrane (7 mm × 10 mm) was used as a sample pad. The 
strips were allowed to dry for 1 hr at 25 °C before use.
Lateral flow assay with aptamer-phage
A 10-fold dilution series of human IgE was prepared in PBS, pH 7.0 with 0.5% bovine 
serum albumin (BSA). Each IgE sample (100 μL) was dispensed onto the sample application 
area of a prepared LFA strip. The strips were then washed with 200 μL LFA buffer (50-μl 
aliquots; 4x) PBS, pH 7.0; 1% Tween-20; 1% Triton; 0.1% PEG-3350) followed by 10 μL 
of the aptamer-phage reporter construct (~109 phage), and finally with 500 μL LFA buffer 
(50-μl aliquots; 10x). Signals were visualized by spotting 25 μL TMB Liquid Substrate 
System for Membranes (Sigma-Aldrich, St. Louis, MO) on each line. The signals were 
allowed to develop for 10 min and then the strips were scanned on a Perfection V600 flatbed 
color scanner (Epson, Long Beach, CA). The scanned images were analyzed using ImageJ’s 
Gel Analysis Tool and by plotting the line intensity profile. The intensity of each line was 
given by the area under each peak that was numerically integrated using ImageJ’s Gel 
Analysis Toolbox. The ratio of the intensity of the test line to that of the control line for each 
strip (T/C) was used as an indicator of signal strength over the background.
RESULTS AND DISCUSSION
Evaluation of aptamer-phage for direct detection of spotted IgE and PBP2a in LFA
Initial LFA experiments tested the binding of the anti-IgE and anti-PBP2a aptamer-phage 
directly to IgE and PBP2a proteins, respectively, spotted on a Fusion 5 membrane. For the 
IgE experiments, 5 μL IgE (0.2 mg/mL) and 5 μL anti-M13 antibodies (0.1 mg/mL) in 50 
mM sodium acetate buffer (pH 3.6) were spotted on the test and control lines, respectively, 
of a Fusion 5 membrane. For the anti-PBP2 aptamer-phage, 5 μL PBP2a protein (0.2 
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mg/mL) was spotted on the test line and anti-M13 antibodies on the control line. The strips 
were dried for 1 hr at room temperature. Aptamer-phage dilutions (10 μl) ranging from 107 
to 109 phage were dispensed onto the sample application area of the LFA strip. The strips 
were washed with 500 μL LFA buffer and signals were obtained by spotting TMB Liquid 
Substrate on each line. As shown in Figure 4, a clear signal was obtained at the anti-M13 
control line for all samples containing >107 aptamer-phage. This result confirms that the 
aptamer-phage moved successfully through the membrane. The signals obtained at the test 
lines using 108 and 107 aptamer-phage were weak, but with 109 phage the signals for both 
IgE and PBP2a were clear and distinguishable from other aptamer-phage concentrations 
(Figure 4). Tests with phage modified with HRP but no aptamer gave no visible test line 
signal with either protein, thus confirming that M13 phage without aptamers are not retained 
non-specifically by IgE or PBP2a protein at the test line but still yield a specific signal at the 
anti-M13 control line.
Lateral flow sandwich immuno-aptamer assay for IgE detection
We next developed a sandwich IgE LFA based on the IgE-dependent capture of phage 
modified with anti-IgE aptamers and HRP on anti-IgE polyclonal antibodies at a test line on 
Fusion 5 strips. Serial dilutions of the IgE test analyte ranging from 0.013-130 ng/mL were 
prepared in PBS at pH 7.0 with 0.5% BSA. Each IgE sample (100 μL) was dispensed onto 
the sample application area of the prepared LFA strips. A clear signal on the anti-M13 
antibody control line for all samples confirmed that the phage reporters had successfully 
moved through the membrane. A signal clearly distinguishable from the no-IgE control was 
obtained at the test line of the strip with 0.13 ng/mL IgE (0.68 pM) (Figure 5, Table S1). 
The relative intensities of the test lines were divided by the control line intensities (T/C) to 
adjust for any background and this ratio was used as the reported LFA signal. The limit of 
detection (LOD) was determined using Student’s t-test from five independent replicate 
LFAs. We report the LOD for IgE detection using aptamer-phage to be at least 0.13 ng/mL, 
defined as the lowest tested concentration that was significantly different from the negative 
control with no IgE at a significance level of α=0.05. Table S2 in the supplementary 
material shows that the average T/C differs between the negative and the positive control at 
a significant level of α=0.05, and we thus reject the null hypothesis for all the IgE 
concentrations except for 0.013 ng/mL. Therefore the LOD of our assay is concluded to be 
at or lower than 0.13 ng/mL, in that the positive control signal from 0.13 ng/mL of the 
analyte concentration is statistically distinguishable from the negative control.
Compared to previously reported assays using the same anti-IgE aptamer, our phage-based 
LFA achieves a greater sensitivity in detecting IgE with a reduction in the LOD by ~230 
times compared to the assay reported by Tran et al. 34 (30 ng/mL), who used an aptamer-
based impedimetric biosensor using a nanocrystalline diamond (NCD) film as a working 
electrode to detect IgE and by ~8 times compared to the assay reported by Wei et al. 35 (10 
ng/mL) who used silver nanoparticles modified with the IgE aptamers to detect captured IgE 
on microarrays with metal-enhanced fluorescence. It is noteworthy that Tran et al. 34 
reported similar LOD for the detection of IgE in buffer and in human serum using this 
aptamer. Initial testing with human IgE spiked into human serum confirms that these 
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samples are compatible with phage transport through the LFA strip, preservation of LOD, 
and specific capture of the phage constructs on the test line (preliminary data not shown).
Currently the most popular FDA-cleared assay for IgE detection in serum is the ELISA-
based ImmunoCAP system, which requires considerable investment in instrumentation and a 
moderately high cost per assay with a detection range of total IgE of 0-100 kU/I (0-240 
ng/mL; 1 kU/I = 2.4 ng/mL). ImmunoCAP Rapid is a related commercially available 
qualitative lateral flow test that measures specific IgE in whole blood and its sensitivity 
ranges between 0.72-1.68 ng/mL. The ALFA (Allergy Lateral Flow Assay) Total IgE test 
from Dr. Fooke Laboratories (GmbH) reports a detection sensitivity of 12 ng/mL in serum 
or whole blood.
Aptamer-phage specificity
The specificity of the aptamer-phage LFA was tested by spotting the unrelated murine IgG1 
anti-hen egg lysozyme antibody, HyHEL-5 36, onto the test line. Neither the no-IgE 
samples, nor 13 ng/mL IgE gave any signals at the HyHEL-5 test line, implying that neither 
IgE nor aptamer-phage bind non-specifically to this unrelated antibody (Figure 6, Strips 1 
and 2). Furthermore, no signal was observed when HyHEL-5 was passed as a mock-analyte 
on an LFA membrane with an anti-IgE test line followed by anti-IgE aptamer-phage (Figure 
6, Strip 7). The strips where IgE was added confirmed that IgE binds specifically to the anti-
IgE test line (Figure 6, Strips 3, 4 and 5) and functionalized aptamer-phage are subsequently 
retained, hence demonstrating the specific performance of the aptamer-phage LFA for IgE 
detection.
The specificity of the IgE LFA was also demonstrated by a competition assay (Figure 6, 
Strip 6). Here IgE (130 ng/mL) was passed through the membrane (with anti-IgE test line 
and anti-M13 control line) followed by an excess amount of soluble anti-IgE aptamer (10 
μM aptamer in 100 μL of LFA buffer) to saturate the binding sites on the captured IgE 
protein and subsequently adding the anti-IgE aptamer-phage reporters. We previously 
confirmed that IgE was captured in the anti-IgE test line, as shown in Figure 6, Strips 3, 4, 
and 6. However, the excess of competing soluble IgE aptamer occupies the sites on the 
captured IgE, so anti-IgE phage cannot bind and hence no signal was observed, indicating 
that phage do not bind non-specifically by interactions other than those mediated by 
aptamer-IgE recognition.
PBP2a aptamer-phage as specificity control for IgE-aptamer-phage reporters
As a control for the specificity of the IgE aptamer-phage construct, we used an aptamer-
phage functionalized with a proprietary aptamer recognizing the Staphylococcus aureus 
penicillin-binding protein, PBP2a. This PBP2a-M13 phage construct was prepared in a 
fashion analogous to that used for the anti-IgE aptamer-phage construct.
IgE (13 ng in 100 μL of LFA buffer) was passed through the strip, followed by the PBP2a-
M13 phage construct. As expected, the anti-PBP2a aptamer on the phage did not recognize 
the IgE protein captured on the test line and hence there was no signal (Figure 7, Strip 6). To 
confirm the performance of the PBP2a-M13 phage construct, strips were made with PBP2a 
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protein and anti-M13 antibodies on the test and control lines, respectively (Figure 7, Strip 2). 
A clear signal was obtained on the strip where the PBP2a-M13 phage construct were 
applied, indicating detection of the target PBP2a protein. As a further control, the strip with 
HRP-phage reporters bearing no PBP2a aptamers did not show any signal, indicating that 
phage do not bind non-specifically to the PBP2a protein (Figure 7, Strip 1). The strips where 
IgE was added reveal that IgE binds specifically to the anti-IgE test line (Figure 7, Strips 4 
& 5) and functionalized aptamer-phage are subsequently retained there, hence demonstrating 
the efficient performance of the aptamer-phage LFA for IgE detection. The test and control 
lines were quantified by ImageJ density’s analysis function.
CONCLUSIONS
We have demonstrated a novel, specific and highly sensitive lateral flow assay for the 
detection of proteins using viral nanoparticles as scaffolds bearing aptamers as bio-
recognition elements. With further refinement, the use of aptamer-phage as reporters in 
lateral flow assays promises a convenient, cost-effective and specific framework for the 
detection of analytes. Compared to antibodies, aptamers have lower production cost, and can 
be easily and rapidly be selected and synthesized. They are chemically more stable, and can 
be selected to have high affinity towards their targets. The 2,700 copies of the M13 coat 
protein provide multiple sites for enzyme conjugation, and thus an enhanced signal per 
individual affinity agent is generated, resulting in increased sensitivities. Phage 
nanoparticles represent versatile scaffolds with high colloidal stability and very low non-
specific binding that can accommodate a variety of recognition and reporter elements, thus 
making them broadly applicable and ultrasensitive bio-detection reporters.
While the aim of the present study was primarily to demonstrate the feasibility and 
performance of aptamer-phage LFAs, the success of this approach suggests that phage 
bearing nucleic acids also could serve as the basis of high-sensitivity lateral-flow nucleic 
acid assays. It is also worth noting that the detection of IgE, used as a model here, has 
clinical value in itself. IgE is known to play an important role in the allergic response and is 
widely reported as a marker of atopic diseases such as asthma, dermatitis and pollenosis 37 . 
Testing of specific IgE, particularly at low levels of IgE, can be helpful in evaluating a 
patient's sensitivity profile and risk factors for other severe conditions such as anaphylaxis.
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Figure 1. 
Biotin-TEG IgE aptamer (secondary structure adapted from Reference 29).
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Figure 2. 
Functionalization of M13 phage with IgE aptamers and Horseradish peroxidase (HRP). 
Phage displaying AviTag peptides are biotinylated using Biotin ligase. Biotinylated phage 
are covalently modified with HRP on the major coat protein pVIII before neutravidin is 
bound to biotinylated AviTag on HRP-labeled phage. Neutravidin-functionalized phage are 
then conjugated with the biotinylated IgE aptamer.
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Figure 3. 
Aptamer-phage lateral flow assay. The M13 phage SAM-AviTag protein, pIII, was 
specifically biotinylated and functionalized with analyte-specific biotinylated aptamers, and 
the M13 coat proteins were functionalized with Horseradish peroxidase. The detection line 
contains IgE-specific antibodies, and the control line has anti-M13 antibodies. Captured 
HRP-labeled phage were detected on the test and control lines using the chromogenic 
substrate, 3’,3,5,5’-tetramethylbenzidine (TMB).
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Figure 4. 
Direct detection of spotted target analytes (PBP2a (A) or IgE (B)) with aptamer-phage. (A) 
PBP2a protein and anti-M13 antibodies were spotted on the test and control lines, 
respectively. (B) IgE protein and anti-M13 antibodies were spotted on the test and control 
lines, respectively. Different concentrations of aptamer-phage constructs were then passed 
through the membranes. Phage bearing HRP reporters but no aptamers (HRP-M13) served 
as a specificity control.
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Figure 5. 
Lateral flow assay with aptamer-phage for IgE detection. Various concentrations of IgE 
(volume: 10 μL) were detected using anti-IgE antibodies at the test line and IgE aptamer-
HRP-phage reporters. Control line consisted of anti-M13 antibodies. Line intensity profiles 
as evaluated by ImageJ density analysis of the LFA strips are shown below each strip. The 
area under each peak was numerically integrated using the ImageJ Gel Analysis Toolbox to 
give the intensity for that line. The intensity of the test line divided by the intensity of the 
control line for each strip is shown below each line intensity profile.
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Figure 6. 
Control for non-specific binding of IgE and aptamer-phage to an unrelated protein (the 
murine anti-lysozyme IgG antibody HyHEL-5). Strips 1 & 2; HyHEL-5 was spotted on the 
test line and anti-M13 antibodies on the control line. IgE protein (100 μL in LFA buffer) was 
passed through the membrane and aptamer-phage were added as reporters. No signal was 
observed on the HyHEL-5 test line. Strips 3, 4 & 5; To confirm specificity and sensitivity of 
the assay, varied concentrations of IgE were passed through the membrane. Strip 6; 
Competition assay where free IgE aptamer was passed on the strip prior to offering the 
aptamer-phage construct; 130 ng/mL IgE in 100 μL of LFA buffer were passed, followed by 
soluble IgE aptamer (10 μM aptamer in 100 μL of LFA buffer) and then the aptamer-phage 
construct was offered. No signal was observed on the test line confirming that soluble anti-
IgE aptamer competes with aptamer-phage for the available binding sites on the IgE protein. 
Strip 7; 100 μL of HyHEL-5 in LFA buffer was passed through the membrane with anti-IgE 
and anti-M13 lines and detected using the IgE aptamer-phage reporter. No signal was 
observed on the HyHEL-5 test line, confirming specificity of the assay. Line intensity 
profiles as evaluated by ImageJ density analysis of the LFA strips. The area under each peak 
was numerically integrated using the ImageJ Gel Analysis Toolbox to give the intensity for 
that line. The intensity of the test line divided by the intensity of the control line for each 
strip is shown below each line intensity profile.
Adhikari et al. Page 15
Anal Chem. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. 
PBP2a aptamer-phage as a specificity control for IgE-aptamer-phage reporters. Strips 1 & 2; 
Strips with PBP2a protein and anti-M13 antibodies on the test and control lines, 
respectively, were made to evaluate the binding of PBP2a-M13 to PBP2a protein. A clear 
signal on the test line of strip 2 indicates binding of the PBP2a-phage to the PBP2a protein. 
Strip 1 with HRP-phage devoid of any signal, confirms that phage do not bind non-
specifically to the PBP2a protein. Strips 3, 4 & 5 show the various concentrations of IgE 
protein (100 μL in LFA buffer) that were used. IgE binds on the anti-IgE test line. Signals on 
the control lines indicate the proper functioning of the assay. Strip 6; A PBP2a-M13 phage 
construct was passed through a strip with anti-IgE and anti-M13 lines. The anti-PBP2a 
aptamer on the phage did not bind to the IgE protein on the test line as indicated by the 
absence of any signal on the test line. Line intensity profiles as plotted by ImageJ density 
analyses of the LFA strips are shown below each figure. The area under each peak was 
numerically integrated using the ImageJ Gel Analysis Toolbox, and the average intensity of 
the test line divided by the intensity of the control line for each strip is also shown below 
each line intensity profile.
Adhikari et al. Page 16
Anal Chem. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
